Sal Daher, CFA

University of Minnesota epidemiologist Michael Osterholm joins us to talk about the state of the pandemic as we head into the holidays.

The acquisition agreement comes exactly two years after the two companies began a wide-ranging alliance focused on developing RNA interference drug for metabolic disorders. The most advanced therapy…

Relying on a controversial legal theory, one state went to trial this week to win $38 billion from pharma wholesalers over opioid monitoring.

Congress’ action this week is a victory for Black maternal health advocates like Charles Johnson, who wants more support for Black mothers.

“We need a greater sense of urgency. It’s not there. Companies are just moving along,” said Jayasree Iyer of Access to Medicines Foundation.

Next year will be a ‘landmark’ one for GlaxoSmithKline, according to CEO Emma Walmsley’s remarks at the 2021 STAT Summit.

Generate Biomedicines has raised $370 million in venture capital from investors keen on its plan to use machine learning in drug discovery.

Researcher Siddhartha Roy was on the ground during the Flint water crisis. He sees lessons in his experience about building trust in science.

Teva Pharmaceuticals recently sold $5 billion in bonds tied directly to its progress on climate change and access to medicines goals.

In the latest edition of STAT Health Tech: prescription VR tools move forward and trouble on the SPAC horizon.